Inflammatory immune cells predict survival, relapse in multiple myeloma

New ‘atlas’ of immune cells in bone marrow cancer lays foundation for more reliable prognosis

2026-01-09

(Press-News.org) A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure. This large immune cell atlas, which includes robust patient outcome data, provides unparalleled new insights into how the immune system interacts with cancerous plasma cells and can be used to determine how aggressive a patient’s multiple myeloma is likely to be. The knowledge may improve survival predictions, guide treatment decisions and help in the development of new immune-based therapies for patients with multiple myeloma.

Co-led by researchers at Washington University School of Medicine in St. Louis in collaboration with the Multiple Myeloma Research Foundation (MMRF) and other leading institutions across the country, the study appears Jan. 9 in the journal Nature Cancer.

“It is time for a better understanding of the immune system in multiple myeloma,” said WashU Medicine co-senior author Li Ding, PhD, the David English Smith Professor of Medicine and a research member of Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine. “In addition to targeting the cancerous plasma cells directly, we also want new and better ways to activate the immune system to attack the malignant cells. This large-scale immune cell atlas will serve as a critical resource to investigators studying multiple myeloma and working to develop better therapies.”

While considered a rare cancer, multiple myeloma is the second most common blood cancer after leukemia, accounting for about 15%-20% of new blood cancer diagnoses in the U.S. annually. Plasma cells are white blood cells in the bone marrow. When they grow out of control, they crowd out healthy blood cells. About 60% of patients are still living five years after diagnosis.

Many new treatment options have emerged for multiple myeloma in recent years that can extend survival for many patients, sometimes for more than a decade. Even so, the disease almost always returns after periods of remission, emphasizing the need for new and better options.

Several of the newest therapies for multiple myeloma are immune system-based, including CAR-T cells and what are known as bispecific antibodies. But researchers suspect there may yet be untapped opportunities for immune-based treatments for multiple myeloma, and the immune cell atlas is a new tool to harness in pursuit of such therapies.

“This immune atlas provides a roadmap for the next generation of myeloma care,” said coauthor and WashU Medicine oncologist Ravi Vij, MD, the Jeffrey S. and Prue H. Gershman Distinguished Professor of Medicine. “As immunotherapies like CAR-T cells and bispecific antibodies become central to treatment, understanding the immune context in which they operate is essential. Clinically, this work lays the foundation for immune-informed risk stratification and rational development of new therapies that not only target the tumor but also restore effective anti-myeloma immunity.”

Vij treats patients with multiple myeloma and other blood cancers at Siteman Cancer Center.

A cell-by-cell catalog of multiple myeloma The research team performed a rigorous and cutting-edge genetic analysis called single-cell RNA sequencing of almost 1.4 million individual plasma and immune cells in bone marrow sampled from 337 newly diagnosed multiple myeloma patients. This type of analysis can reveal how individual immune cells may function — or become dysfunctional — in the context of multiple myeloma.

The data describe patients enrolled in MMRF’s CoMMpass Study, which is the first large-scale, long-running study of patients with multiple myeloma focused on analyzing disease progression and treatment response based on the genomic and molecular profiles of the patients. WashU Medicine is one of multiple sites participating in the CoMMpass Study.

The investigators found that patients with certain types of immune cells in their bone marrow at diagnosis were more likely than others to relapse quickly, meaning their cancer returned soon after a first round of treatment. The researchers identified signaling patterns between the cancer cells and immune cells that drive inflammation, which might be boosting the cancer’s growth in patients with aggressive disease.

The team also identified a type of T cell that had stopped working as expected and, rather than attacking the tumor as it should, acted to suppress immune activity against the cancer. Together, these findings could help make prognosis more accurate and aid in selecting the best therapies.

“This immune atlas represents the power of collaborative science,” said co-senior author and MMRF Chief Scientific Officer George Mulligan, PhD. “The MMRF’s CoMMpass Study, combined with the expertise from investigators at WashU Medicine and leading institutions across the country, has created an unprecedented resource that will accelerate discovery and improve outcomes for myeloma patients.”

Importantly, the researchers showed that knowledge of the immune environment in a patient’s bone marrow could improve upon current methods for predicting which patients are most likely to experience an aggressive course of the disease and have shortened survival. Such predictions can help guide treatment decisions in terms of matching the intensity of the treatment with the aggressiveness of the cancer.

Current methods for determining whether a patient has high-risk multiple myeloma versus standard risk rely on knowing the genetic features of the cancer cells combined with clinical aspects of the patient’s health. The new study found that adding an immune component to this analysis would likely improve the accuracy of the categorization.

“More work is needed to develop specific immune-based blood tests, for example, that clinicians could order to better identify the aggressiveness of a particular case of multiple myeloma and help them select the best treatments for that patient,” Ding said. “This immune cell atlas fills a gap in knowledge that is needed to develop these types of new clinical tools.”

The MMRF designed and funded this research, which involved collaboration among the Georgia Institute of Technology, Emory University, Harvard Medical School and the Icahn School of Medicine at Mount Sinai.

Pilcher WC, Yao L, Gonzalez-Kozlova E, Pita-Juarez Y, Karagkouni D, Acharya CR, Michaud ME, Hamilton M, Nanda S, Song Y, Sato K, Wang JT, Satpathy S, Ma Y, Schulman J, D’Souza D, Jayasinghe RG, Ohlstrom D, Ferguson KE, Cheloni G, Bakhtiari M, Pabustan N, Nie K, Foltz JA, Saldarriaga I, Alaaeldin R, Lepisto E, Chen R, Fiala MA, Thomas BE, Cook A, Vieira Dos Santos J, Chiang I, Figueiredo I, Fortier J, Slade M, Oh ST, Rettig MP, Anderson E, Li Y, Dasari S, Strausbauch MA, Simon VA, Immune Atlas Consortium, Radkevich E, Rahman AH, Chen Z, Lagana A, DiPersio JF, Rosenblatt J, Kim-Schulze S, Lonial S, Kumar S, Bhasin SS, Kourelis T, Dhodapkar MV, Vij R, Avigan D, Cho HJ, Mulligan G, Ding L, Gnjatic S, Vlachos IS, Bhasin M. A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma. Nature Cancer. Jan. 9, 2026. DOI: 10.1038/s43018-025-01072-4.

This work was designed and supported by the Multiple Myeloma Research Foundation; the Myeloma Solutions Fund; the Paula C. and Rodger O. Riney Blood Cancer Research Fund; and the National Institutes of Health (NIH), grant numbers U24CA224319, U01DK124165, P30CA196521, R50CA211466, R35CA210084, 5K12CA090628, U24CA211006, U2CCA233303, PJ000021702, R01CA258776 and UL1TR004419. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

About WashU Medicine

WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with more than 3,000 faculty. Its National Institutes of Health (NIH) research funding portfolio is the second largest among U.S. medical schools and has grown 83% since 2016. Together with institutional investment, WashU Medicine commits well over $1 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently among the top five in the country, with more than 2,000 faculty physicians practicing at 130 locations. WashU Medicine physicians exclusively staff Barnes-Jewish and St. Louis Children’s hospitals — the academic hospitals of BJC HealthCare — and Siteman Cancer Center, a partnership between BJC HealthCare and WashU Medicine and the only National Cancer Institute-designated comprehensive cancer center in Missouri. WashU Medicine physicians also treat patients at BJC’s community hospitals in our region. With a storied history in MD/PhD training, WashU Medicine recently dedicated $100 million to scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in every medical subspecialty as well as physical therapy, occupational therapy, and audiology and communications sciences.

END

ELSE PRESS RELEASES FROM THIS DATE:

New test shows which antibiotics actually work

2026-01-09

Drugs that act against bacteria are mainly assessed based on how well they inhibit bacterial growth under laboratory conditions. A critical factor, however, is whether the active substances actually kill the pathogens in the body. Researchers at the University of Basel have presented a new method for measuring how effectively antibiotics kill bacteria. Antibiotic-resistant bacteria are one of the biggest health problems of our time. Due to mutations, bacteria are increasingly resisting the effects of common drugs, making these infections increasingly difficult to treat. But even ...

Most Alzheimer’s cases linked to variants in a single gene

2026-01-09

Potentially more than 90% of Alzheimer’s disease cases would not occur without the contribution of a single gene (APOE), according to a new analysis led by UCL researchers. The scientists also found that close to half of all dementia cases would probably not arise without the gene’s influence. The researchers say that the findings, published today in npj Dementia, highlight this gene (and the protein it produces) as a powerful yet under-recognised target for drug development, which could have the scope to prevent or treat a large proportion of all dementia. The APOE gene has long been implicated in Alzheimer’s disease. There are three common ...

Finding the genome's blind spot

2026-01-09

EMBARGOED UNTIL 9 January 2026, 11 AM CET, 5 AM ET Basel, 9 January 2026 – Retinitis pigmentosa (RP) is a genetic eye disorder affecting around one in 5,000 people worldwide. It typically begins with night blindness in youth and progresses to tunnel vision as daylight-sensing photoreceptor cells in the retina gradually die, potentially leading to blindness over time. Although more than a hundred genes have been linked to RP, the genetic cause remains undiagnosed in ~30-40% of patients, even after extensive DNA testing. For many families, this ...

The secret room a giant virus creates inside its host amoeba

2026-01-09

Kyoto, Japan -- A virus relies on the host's translation machinery to replicate itself and become infectious. Translation efficiency partially depends on the usage of a codon, or sequence of three nucleotides, that matches the cellular pool of tRNA, key molecules in translation. Using rare codons that are poorly supported by the cellular tRNA pool tends to induce ribosome pausing and mRNA instability, often weakening the virus. Yet many eukaryotic viruses use a codon pattern that deviates from their host's while still relying on the host's translation mechanism. Theoretically this mismatch should hinder viral ...

World’s vast plant knowledge not being fully exploited to tackle biodiversity and climate challenges, warn researchers

2026-01-09

An international group of researchers says that biodiversity conservation and scientific research are not benefiting from the vast knowledge about the world’s plants held by botanic gardens, because of fragmented data systems and a lack of standardisation. In a new report published today in the journal Nature Plants, researchers based at more than 50 botanic gardens and living plant collections warn that a patchwork of incompatible, or even absent, data systems is undermining global science and conservation at a critical moment. They call for a unified and equitable global data ...

New study explains the link between long-term diabetes and vascular damage

2026-01-09

The longer a person has type 2 diabetes, the greater the risk of cardiovascular disease. A new study from Karolinska Institutet, published in the journal Diabetes, shows that changes in red blood cells may be an important explanation, and identifies a specific molecule as a possible biomarker. People with type 2 diabetes are at increased risk of heart attack and stroke, and the risk increases the longer they have lived with the disease. Previous research has shown that red blood cells can affect blood vessel function in diabetes. Now, a new study shows that the duration of the disease plays a decisive ...

Ocean temperatures reached another record high in 2025

2026-01-09

A new international analysis published in Advances in Atmospheric Sciences on 9 January finds that the Earth’s ocean stored more heat in 2025 than in any year since modern measurements began. The 2025 heat increase was 23 Zetta Joules (23,000,000,000,000,000,000,000 Joules of energy), which is equivalent to ~37 years of global primary energy consumption at the 2023 level (~620 Exa Joules per year). The finding is the result of a major international collaboration, involving more than 50 scientists from 31 research ...

Dynamically reconfigurable topological routing in nonlinear photonic systems

2026-01-09

Topological photonics has emerged as a powerful paradigm for achieving robust light transport that is immune to imperfections, disorder, and structural defects. By harnessing principles from condensed matter physics, topological photonic systems support edge modes that guide light along boundaries without backscattering — a feature that has significant implications for resilient optical communication and information processing. However, most demonstrations of topological photonics have been confined to linear and static settings, where the transport pathways are fixed once the device is fabricated. This rigidity presents a major limitation for practical ...

Crystallographic engineering enables fast low‑temperature ion transport of TiNb2O7 for cold‑region lithium‑ion batteries

2026-01-09

As fast-charging lithium-ion batteries race toward sub-zero markets, the anode bottleneck—graphite plating risk and Li4Ti5O12 capacity ceiling—intensifies. Now, researchers from Harbin Institute of Technology, led by Prof. Yan Zhang and Prof. Shuaifeng Lou, unveil an Sb/Nb co-doped TiNb2O7 (TNO) anode that unlocks 140 mAh g-1 at 20 C and 500 stable cycles at −30 °C. Published in Nano-Micro Letters, the work delivers a practical pouch cell delivering 1.14 Ah at 17 C with 93.8 % retention ...

Ultrafast sulfur redox dynamics enabled by a PPy@N‑TiO2 Z‑scheme heterojunction photoelectrode for photo‑assisted lithium–sulfur batteries

2026-01-09

While lithium–sulfur batteries (LSBs) promise 2600 Wh kg⁻¹, the sluggish liquid-solid conversion of polysulfides keeps practical capacities far below theory. Now, researchers at Northwestern Polytechnical University, led by Prof. Yibo He, report a free-standing PPy@N-TiO2/Carbon-Cloth photocathode that harvests sunlight to co-drive sulfur redox, delivering 1 653 mAh g-1 (98.7 % of theory) and 333 mAh g-1 after 5 h of pure photo-charging. Published in Nano-Micro Letters, the work realizes dual-mode energy harvesting in a single cell. Why Photo-Assisted Strategy Matters Polysulfide ...

Inflammatory immune cells predict survival, relapse in multiple myeloma

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: